Miconazole mucoadhesive tablets: a novel delivery system.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22495075.
- Also identified by DOI 10.1093/cid/cis205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.
Medical subject headings
- Antifungal Agents
- Candidiasis, Oral
- Drug Delivery Systems
- Miconazole
- Tablets